Get emailed when MDGL changes direction
Insider selling: $221,672,503 sold by 16 insiders (30d)
Est. revisions:
+0.0%
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net -3.4)
Factor Model
net -3.4 6.4 / 10
Est. Revisions
-1.0
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
-1.0
Narrative Gap
-0.5
First-in-class MASH drug Rezdiffra drives $958M launch year
Watch: Track sequential patient growth and revenue per patient in Q1 2026 earnings to gauge whether the launch is sustaining momentum. International rollout cadence — particularly in major European markets — will signal how quickly Madrigal can scale beyond the US.
Madrigal Pharmaceuticals posted $958.4 million in 2025 revenue, powered entirely by Rezdiffra — the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis. Q4 alone brought in $321.1 million, more than triple the prior year's quarterly run rate. The patient base expanded to over 36,250 by year-end, up from roughly 29,500 in Q3. Patent exclusivity now runs through 2045, and the company kicked off international expansion with a launch in Germany.
Rezdiffra's launch validates a massive unmet need in MASH — a liver disease affecting millions with no prior approved therapy. The accelerating patient uptake and locked-in patent runway through 2045 position Madrigal to own this category for decades, with the German rollout signaling the start of a global revenue opportunity.
Evidence
4d ago
Insider sell by FRIEDMAN PAUL A (MDGL): $13,694,158
4d ago
Insider sell by TAUB REBECCA M.D. (MDGL): $10,297,573
4d ago
Insider buy by BAKER BROS ADVISORS, L.P. (MDGL): $36,941,197
4d ago
Insider buy by BAKER BROS ADVISORS, L.P. (MDGL): $24,979,827
4d ago
Insider sell by FRIEDMAN PAUL A (MDGL): $47,825,149
4d ago
Insider sell by FRIEDMAN PAUL A (MDGL): $16,631,386
4d ago
Insider sell by TAUB REBECCA M.D. (MDGL): $16,509,032
4d ago
Insider sell by FRIEDMAN PAUL A (MDGL): $10,198,844
6 older signals
4d ago
Insider sell by TAUB REBECCA M.D. (MDGL): $10,278,098
4d ago
Insider sell by FRIEDMAN PAUL A (MDGL): $12,808,957
Fundamentals & Data ▾
Madrigal Pharmaceuticals, Inc.
Healthcare · Biotechnology
Mkt Cap
$12B
Beta
-1.01
52w Range
$265.00 - $615.00
Short Interest
3.9M 19.76%
Days to Cover
10.6 +9%
Technicals
downtrend
from 52w Hi
0.0%
1w return
+2.4%
Insiders
selling
0B / 11S
EPS Estimate
$-4.14
+0.0% 30d
0up / 2dn
Est. Dispersion
17%
5 analysts
Analyst Target
$673
$529 - $964
Options P/C
1.50
Insider Cluster
strong sell
1B / 10S
Fund Convergence
strong
D.E. Shaw, Citadel, Renaissance, Bridgewater
Financials
Revenue
$321M +211% YoY
FCF
$-133M
Gross Margin
92%
Op Margin
-19%
Momentum:
decelerating
Top Holders
D.E. Shaw
$269M
Citadel
$107M
Renaissance
$49M
Bridgewater
$11M
Recent Filings & Data
insider trade
120
net selling
· $221,672,503 sold
· $61,921,024 bought
16 insiders · 120 transactions (30d)
Recent transactions
HUNTSMAN CAROLE A · sell · $180,983
KELLEY SHANNON T · sell · $155,498
TAUB REBECCA M.D. · sell · $212,083
SIBOLD WILLIAM JOHN · sell · $718,316
DIER MARDI C · sell · $853,993
HUNTSMAN CAROLE A · award
KELLEY SHANNON T · award
SIBOLD WILLIAM JOHN · award
DIER MARDI C · award
SOERGEL DAVID M.D. · award
DIER MARDI C · sell · $505,389
LEVY RICHARD S · exercise · $18,400
HUNTSMAN CAROLE A · sell · $449,339
TAUB REBECCA M.D. · sell · $318,596
LEVY RICHARD S · exercise · $65,840
SIBOLD WILLIAM JOHN · sell · $776,546
KELLEY SHANNON T · sell · $344,173
TAUB REBECCA M.D. · sell · $1,098,343
THAKKAR RITA · award
FRIEDMAN PAUL A · sell · $12,808,957
FRIEDMAN PAUL A · exercise · $387,416
FRIEDMAN PAUL A · sell · $154,348
FRIEDMAN PAUL A · exercise · $4,424
TAUB REBECCA M.D. · sell · $9,617,312
TAUB REBECCA M.D. · exercise · $290,878
TAUB REBECCA M.D. · sell · $132,080
TAUB REBECCA M.D. · exercise · $3,792
FRIEDMAN PAUL A · sell · $13,694,158
FRIEDMAN PAUL A · exercise · $391,840
TAUB REBECCA M.D. · other
TAUB REBECCA M.D. · sell · $10,297,573
TAUB REBECCA M.D. · exercise · $294,670
SIBOLD WILLIAM JOHN · sell · $1,380,816
SIBOLD WILLIAM JOHN · other
DIER MARDI C · sell · $2,413,416
DIER MARDI C · exercise · $1,050,052
HUNTSMAN CAROLE A · sell · $1,082,986
LEVY RICHARD S · sell · $4,428,198
LEVY RICHARD S · exercise · $117,160
BATE KENNETH M · sell · $8,027,354
BATE KENNETH M · exercise · $3,399,036
SIBOLD WILLIAM JOHN · sell · $3,243,741
SIBOLD WILLIAM JOHN · sell · $3,047,756
BAKER BROS ADVISORS, L.P. · buy · $36,941,197
KELLEY SHANNON T · sell · $479,627
BAKER BROS ADVISORS, L.P. · buy · $24,979,827
BATE KENNETH M · sell · $3,652,009
WALTERMIRE ROBERT E. · sell · $120,847
BATE KENNETH M · exercise · $164,600
FRIEDMAN PAUL A · sell · $47,825,149
FRIEDMAN PAUL A · exercise · $1,220,675
FRIEDMAN PAUL A · sell · $16,631,386
FRIEDMAN PAUL A · exercise · $442,336
TAUB REBECCA M.D. · sell · $16,509,032
TAUB REBECCA M.D. · exercise · $439,075
BRENNAN DANIEL J · award
FRIEDMAN PAUL A · sell · $490,044
FRIEDMAN PAUL A · exercise · $13,230
TAUB REBECCA M.D. · sell · $350,005
TAUB REBECCA M.D. · exercise · $9,450
FRIEDMAN PAUL A · sell · $10,198,844
FRIEDMAN PAUL A · exercise · $272,878
TAUB REBECCA M.D. · sell · $10,278,098
TAUB REBECCA M.D. · exercise · $275,004
FRIEDMAN PAUL A · award
BATE KENNETH M · award
FOUSE JACQUALYN A. · award
LEVY RICHARD S · award
DALY JAMES M. · award
BAKER BROS ADVISORS, L.P. · award
SOERGEL DAVID M.D. · award
CRAVES FREDERICK B · sell · $5,082,480
CRAVES FREDERICK B · exercise · $1,282,478
FOUSE JACQUALYN A. · award
DIER MARDI C · sell · $83,344
WALTERMIRE ROBERT E. · award
WALTERMIRE ROBERT E. · sell · $4,817,104
WALTERMIRE ROBERT E. · exercise · $1,234,766
HUNTSMAN CAROLE A · award
KELLEY SHANNON T · award
TAUB REBECCA M.D. · award
SIBOLD WILLIAM JOHN · award
DIER MARDI C · award
HUNTSMAN CAROLE A · sell · $597,840
KELLEY SHANNON T · sell · $139,025
DIER MARDI C · sell · $637,248
WALTERMIRE ROBERT E. · sell · $418,488
BATE KENNETH M · sell · $7,128,759
BATE KENNETH M · exercise · $1,325,287
DALY JAMES M. · sell · $5,375,126
DALY JAMES M. · exercise · $1,282,478
WALTERMIRE ROBERT E. · sell · $34,530
HUNTSMAN CAROLE A · sell · $116,328
TAUB REBECCA M.D. · sell · $217,236
SIBOLD WILLIAM JOHN · sell · $531,020
KELLEY SHANNON T · sell · $75,735
TAUB REBECCA M.D. · sell · $461,789
CRAVES FREDERICK B · sell · $1,135,122
CRAVES FREDERICK B · sell · $1,191,028
HUNTSMAN CAROLE A · sell · $218,041
LEVY RICHARD S · sell · $1,750,000
LEVY RICHARD S · exercise · $36,800
LEVY RICHARD S · sell · $1,504,703
CRAVES FREDERICK B · other
SIBOLD WILLIAM JOHN · sell · $1,551,490
KELLEY SHANNON T · award
CRAVES FREDERICK B · award
FRIEDMAN PAUL A · award
BATE KENNETH M · award
LEVY RICHARD S · award
DALY JAMES M. · award
BAKER BROS ADVISORS, L.P. · award
WALTERMIRE ROBERT E. · sell · $532,000
WALTERMIRE ROBERT E. · exercise · $165,471
WALTERMIRE ROBERT E. · sell · $570,000
WALTERMIRE ROBERT E. · exercise · $175,840
CRAVES FREDERICK B · other
WALTERMIRE ROBERT E. · sell · $239,668
CRAVES FREDERICK B · sell · $4,787,404
CRAVES FREDERICK B · exercise · $2,316,844
14 signals · latest 4d ago
Get alerted when MDGL changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.